Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 1
2001 1
2002 3
2004 2
2005 1
2006 1
2007 1
2009 5
2010 2
2011 3
2012 5
2013 5
2014 15
2015 26
2016 58
2017 97
2018 142
2019 171
2020 223
2021 299
2022 267
2023 361
2024 415
2025 582
2026 402

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,800 results

Results by year

Filters applied: . Clear all
Page 1
Treating cancer with selective CDK4/6 inhibitors.
O'Leary B, Finn RS, Turner NC. O'Leary B, et al. Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31. Nat Rev Clin Oncol. 2016. PMID: 27030077 Review.
Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies to be identified. Extending the use of CDK4/6 inh …
Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable r …
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.
Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE. Portman N, et al. Endocr Relat Cancer. 2019 Jan;26(1):R15-R30. doi: 10.1530/ERC-18-0317. Endocr Relat Cancer. 2019. PMID: 30389903 Review.
Three inhibitors of CDK4/6 kinases were recently FDA approved for use in combination with endocrine therapy, and they significantly increase the progression-free survival of patients with advanced estrogen receptor-positive (ER+) breast cancer i …
Three inhibitors of CDK4/6 kinases were recently FDA approved for use in combination with endocrine therapy, and they s …
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Huerga Sanchez I, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Kudo R, et al. Cancer Cell. 2024 Nov 11;42(11):1919-1935.e9. doi: 10.1016/j.ccell.2024.09.009. Epub 2024 Oct 10. Cancer Cell. 2024. PMID: 39393354 Free PMC article.
Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of patients experience long-term disease control. ...Human breast cancer models reveal that p53 loss does not alter CDK4/6 …
Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of pat …
Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer.
Luo L, Yang P, Mastoraki S, Rao X, Wang Y, Kettner NM, Raghavendra AS, Tripathy D, Damodaran S, Hunt KK, Wang J, Li Z, Keyomarsi K. Luo L, et al. Mol Cancer. 2025 Feb 15;24(1):48. doi: 10.1186/s12943-025-02226-9. Mol Cancer. 2025. PMID: 39955556 Free PMC article.
BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the standard treatment for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (mBC). ...These genes, including HSP90 and HSPA8 …
BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the standard treatment for pa …
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer.
Herrera-Abreu MT, Guan J, Khalid U, Ning J, Costa MR, Chan J, Li Q, Fortin JP, Wong WR, Perampalam P, Biton A, Sandoval W, Vijay J, Hafner M, Cutts R, Wilson G, Frankum J, Roumeliotis TI, Alexander J, Hickman O, Brough R, Haider S, Choudhary J, Lord CJ, Swain A, Metcalfe C, Turner NC. Herrera-Abreu MT, et al. Nat Commun. 2024 Nov 5;15(1):9550. doi: 10.1038/s41467-024-53837-7. Nat Commun. 2024. PMID: 39500869 Free PMC article.
CDK4/6 inhibition in combination with endocrine therapy is the standard of care for estrogen receptor (ER+) breast cancer, and although cytostasis is frequently observed, new treatment strategies that enhance efficacy are required. ...Lipid peroxidatio …
CDK4/6 inhibition in combination with endocrine therapy is the standard of care for estrogen receptor (ER+) breast c …
O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer.
Zhang Y, Zhou S, Kai Y, Zhang YQ, Peng C, Li Z, Mughal MJ, Julie B, Zheng X, Ma J, Ma CX, Shen M, Hall MD, Li S, Zhu W. Zhang Y, et al. Nat Commun. 2024 Jul 3;15(1):5597. doi: 10.1038/s41467-024-49875-w. Nat Commun. 2024. PMID: 38961064 Free PMC article.
Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal role in cell cycle and cancer development. Targeting CDK4/6 has demonstrated promising effects against breast cancer. However, resistance to CDK4/6 in …
Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal role in cell cycle and cancer development. Targeting …
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors.
Tracy PD, Bopp E, Milner E, Garrido-Castro AC, Giordano A, Mayer EL, Tolaney SM, Tarantino P, Schlam I. Tracy PD, et al. Curr Oncol Rep. 2025 Jul;27(7):915-933. doi: 10.1007/s11912-025-01689-9. Epub 2025 May 28. Curr Oncol Rep. 2025. PMID: 40434676 Review.
PURPOSE OF REVIEW: Since the introduction of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) as the first-line treatment for metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative …
PURPOSE OF REVIEW: Since the introduction of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine thera …
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer.
Migliaccio I, Guarducci C, Malorni L. Migliaccio I, et al. Adv Exp Med Biol. 2025;1464:475-493. doi: 10.1007/978-3-031-70875-6_23. Adv Exp Med Biol. 2025. PMID: 39821039 Review.
The cyclin-dependent kinases 4 and 6 inhibitors are the mainstay of treatment for patients with hormone receptor-positive and HER2-negative breast cancer. ...Here we summarize present knowledge on the cyclin-dependent kinases 4 and 6 inhibitors' mechan …
The cyclin-dependent kinases 4 and 6 inhibitors are the mainstay of treatment for patients with hormone receptor-positive and HER2-ne …
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Rugo HS, et al. Lancet Oncol. 2021 Apr;22(4):489-498. doi: 10.1016/S1470-2045(21)00034-6. Lancet Oncol. 2021. PMID: 33794206 Clinical Trial.
METHODS: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4 …
METHODS: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negati …
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer.
Sahin TK, Rizzo A, Guven DC, Aksoy S. Sahin TK, et al. Cancer Treat Rev. 2025 Apr;135:102924. doi: 10.1016/j.ctrv.2025.102924. Epub 2025 Mar 20. Cancer Treat Rev. 2025. PMID: 40121890 Review.
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard first-line treatment for hormone receptor-positive (HR + ) and HER2-negative metastatic breast cancer (mBC). ...Combination strategies involving …
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard first-line treatment f …
2,800 results